Logan Capital Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Logan Capital Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-6,400	Closed	-$301K	–	293
2018 Q3	$301K	Buy	6,400 +400	+7%	+$22.3K	0.02%	263
2018 Q2	$296K	Buy	+6,000	New	+$227K	0.02%	260
2015 Q3	–	Sell	-10,000	Closed	-$315K	–	295
2015 Q2	$315K	Buy	10,000 +1,100	+12%	+$32.4K	0.02%	266
2015 Q1	$261K	Buy	+8,900	New	+$209K	0.02%	258

Other funds holding MRTX

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Logan Capital Management's MRTX Position: Q4 2018 in Review

Logan Capital Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2018, closing a stake of 6,400 shares — an estimated $301K sold.

Logan Capital Management first reported a position in MRTX in Q1 2015 and held it in 4 quarters. The position peaked at $315K in Q2 2015. 112 funds tracked by Wall St. Rank hold MRTX as of Q4 2018.

Logan Capital Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
Logan Capital Management sold 6,400 Mirati Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $301K.
Logan Capital Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2015 and held it in 4 quarters.
Logan Capital Management's Mirati Therapeutics, Inc. Common Stock position peaked at $315K in Q2 2015.
112 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Logan Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.